贝伐珠单抗治疗晚期乳腺癌患者：我们已经到达何处？
Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?
机构信息
Oncology Center, St. Augustinus Hospital, Oosterveldlaan 24, 2610 Wilrijk-Antwerp, Belgium.
出版信息
Ther Adv Med Oncol. 2010 Sep;2(5):331-42. doi: 10.1177/1758834010376301.
Abstract
Vast preclinical and clinical evidence has made angiogenesis one of the hallmarks of cancer. In many human tumours, vascular endothelial growth factor (VEGF) has been identified as the crucial mediator of this process. Initial studies suggested that angiogenesis, and VEGF in particular, could be inhibited without the risk of major side effects. After the pivotal data in first-line studies in patients with colorectal cancer, numerous clinical trials have been undertaken in patients with breast cancer. This review attempts to update these investigations and define the role of anti-VEGF antibody treatment in advanced breast cancer.
摘要
大量的临床前和临床证据使血管生成成为癌症的特征之一。在许多人类肿瘤中，血管内皮生长因子（VEGF）已被确定为这一过程的关键介质。最初的研究表明，血管生成，特别是 VEGF，可以被抑制，而不会有产生重大副作用的风险。在一线治疗结直肠癌患者的关键数据公布后，在乳腺癌患者中进行了许多临床试验。本文试图更新这些研究结果，并确定抗 VEGF 抗体治疗在晚期乳腺癌中的作用。
相似文献
1
Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?贝伐珠单抗治疗晚期乳腺癌患者：我们已经到达何处？
Ther Adv Med Oncol. 2010 Sep;2(5):331-42. doi: 10.1177/1758834010376301.
2
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.针对内分泌难治性或耐药性转移性乳腺癌的血管内皮生长因子（VEGF）靶向治疗。
Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD008941. doi: 10.1002/14651858.CD008941.pub2.
3
The role of antiangiogenetic agents in the treatment of breast cancer.抗血管生成药物在乳腺癌治疗中的作用。
Curr Med Chem. 2011;18(33):5022-32. doi: 10.2174/092986711797636072.
4
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.血管内皮生长因子（VEGF）作为贝伐单抗在癌症治疗中的靶点：从生物学机制到临床应用
Curr Med Chem. 2006;13(16):1845-57. doi: 10.2174/092986706777585059.
5
Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.贝伐珠单抗在结直肠癌生长及其不良反应中的作用：综述。
World J Gastroenterol. 2013 Aug 21;19(31):5051-60. doi: 10.3748/wjg.v19.i31.5051.
6
Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.循环血管内皮生长因子受体 2/pAkt 阳性细胞作为抗血管生成剂治疗转移性结直肠癌的功能药效标志物。
Invest New Drugs. 2013 Feb;31(1):1-13. doi: 10.1007/s10637-012-9817-7. Epub 2012 Apr 27.
7
Integration of novel agents in the treatment of colorectal cancer.新型药物在结直肠癌治疗中的整合应用。
Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. doi: 10.1007/s00280-004-0884-0.
8
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.靶向血管内皮生长因子的单克隆抗体：癌症治疗的现状与未来挑战
BioDrugs. 2009;23(5):289-304. doi: 10.2165/11317600-000000000-00000.
9
Bevacizumab in the treatment of breast cancer.贝伐珠单抗治疗乳腺癌。
Cancer Treat Rev. 2010 Feb;36(1):75-82. doi: 10.1016/j.ctrv.2009.10.007. Epub 2009 Nov 22.
10
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.西妥昔单抗（单药或联合化疗）、贝伐珠单抗（联合非奥沙利铂化疗）和帕尼单抗（单药治疗）用于一线化疗后转移性结直肠癌治疗的临床疗效和成本效果评价（技术评估 150 号报告的部分回顾和技术评估 118 号报告的综述）：系统评价和经济模型。
Health Technol Assess. 2013 Apr;17(14):1-237. doi: 10.3310/hta17140.
引用本文的文献
1
Short-term study on in-use stability of opened bevacizumab biosimilar PF-06439535 vials.贝伐单抗生物类似药PF-06439535开封小瓶使用稳定性的短期研究
Eur J Hosp Pharm. 2022 Jul 19;31(2):135-42. doi: 10.1136/ejhpharm-2021-003198.
2
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.一项关于紫杉醇-贝伐单抗及维持治疗作为HER2阴性转移性乳腺癌一线治疗方案的真实世界多中心回顾性研究。
J Cell Physiol. 2017 Jun;232(6):1571-1578. doi: 10.1002/jcp.25685. Epub 2016 Nov 30.
3
Vaccines targeting the neovasculature of tumors.靶向肿瘤新生血管的疫苗。
Vasc Cell. 2011 Mar 8;3(1):7. doi: 10.1186/2045-824X-3-7.
本文引用的文献
1
N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.N0539 期临床试验：氟维司群联合贝伐珠单抗治疗既往接受芳香化酶抑制剂治疗的转移性乳腺癌患者：一项由美国北部肿瘤协作组（现更名为联盟）开展的研究。
Ann Oncol. 2013 Oct;24(10):2548-2554. doi: 10.1093/annonc/mdt213. Epub 2013 Jun 24.
2
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group.一项纳入贝伐珠单抗的Ⅱ期临床试验，在淋巴结阳性乳腺癌患者中采用密集剂量多柔比星和环磷酰胺序贯紫杉醇：由东部肿瘤协作组协调的一项试验。
Ann Oncol. 2012 Feb;23(2):331-7. doi: 10.1093/annonc/mdr344. Epub 2011 Aug 4.
3
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).贝伐珠单抗联合每周紫杉醇脂质体与卡培他滨治疗局部复发或转移性乳腺癌的一线治疗方案：一项多中心、单臂 II 期试验（SAKK 24/06）。
Ann Oncol. 2011 Jan;22(1):80-85. doi: 10.1093/annonc/mdq319. Epub 2010 Jul 1.
4
Pathways mediating VEGF-independent tumor angiogenesis.介导 VEGF 非依赖性肿瘤血管生成的途径。
Cytokine Growth Factor Rev. 2010 Feb;21(1):21-6. doi: 10.1016/j.cytogfr.2009.11.003. Epub 2009 Dec 11.
5
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.接受节拍化疗联合贝伐单抗治疗的乳腺癌患者中血管生成生长因子和循环内皮细胞的预测潜力
Clin Cancer Res. 2009 Dec 15;15(24):7652-7657. doi: 10.1158/1078-0432.CCR-09-1493.
6
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.北美癌症治疗合作组（NCCTG）N0432 研究：多西紫杉醇联合卡培他滨和贝伐珠单抗一线治疗转移性乳腺癌的Ⅱ期临床试验。
Ann Oncol. 2010 Feb;21(2):269-274. doi: 10.1093/annonc/mdp512. Epub 2009 Nov 9.
7
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.来曲唑联合贝伐珠单抗治疗转移性乳腺癌的可行性研究。
J Clin Oncol. 2010 Feb 1;28(4):628-33. doi: 10.1200/JCO.2009.21.8784. Epub 2009 Oct 19.
8
Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease.血管生成与人类乳腺导管疾病中增生的发生有关。
Br J Cancer. 2009 Aug 18;101(4):666-72. doi: 10.1038/sj.bjc.6605196. Epub 2009 Jul 21.
9
VEGF kinase inhibitors: how do they cause hypertension?血管内皮生长因子激酶抑制剂：它们是如何导致高血压的？
Am J Physiol Regul Integr Comp Physiol. 2009 Jul;297(1):R1-5. doi: 10.1152/ajpregu.90502.2008. Epub 2009 May 13.
10
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.术前多西他赛联合或不联合贝伐单抗用于局部晚期乳腺癌的血管靶向治疗方案：对血管生成生物标志物的影响
Clin Cancer Res. 2009 May 15;15(10):3583-90. doi: 10.1158/1078-0432.CCR-08-2917. Epub 2009 May 5.
Zotero 插件